NCT06768697View on ClinicalTrials.gov

Safety and Immunogenicity Evaluation of the Recombinant Flagellin Protein Adjuvant

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 30, 2024

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions
COVID - 19
Interventions
BIOLOGICAL

KFD1(0µg )

SARS-CoV-2 subunit mucosal vaccine adjuvanted with flagellin protein(0µg + 80µg)

BIOLOGICAL

KFD1(20µg)

SARS-CoV-2 subunit mucosal vaccine adjuvanted with flagellin protein(20µg + 80µg)

BIOLOGICAL

KFD1(40µg)

SARS-CoV-2 subunit mucosal vaccine adjuvanted with flagellin protein(40µg + 80µg)

BIOLOGICAL

KFD1(80µg)

SARS-CoV-2 subunit mucosal vaccine adjuvanted with flagellin protein(80µg + 80µg)

Trial Locations (1)

201508

Shanghai Public Health Clinical Center,Fudan University, Shanghai

All Listed Sponsors
lead

Shanghai Public Health Clinical Center

OTHER_GOV